SCHEMBL20150113

SCHEMBL20150113

COc1c(-c2ncco2)cccc1C(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 5/20 0.38
TUBB P07437 5/20 0.38
TUBA3C P0DPH7 5/20 0.38
TUBA1B P68363 5/20 0.38
TUBA4A P68366 5/20 0.38
TUBB4B P68371 5/20 0.38
TUBB3 Q13509 5/20 0.38
TUBB2A Q13885 5/20 0.38
TUBB8 Q3ZCM7 5/20 0.38
TUBA3E Q6PEY2 5/20 0.38
TUBA1A Q71U36 5/20 0.38
TUBA1C Q9BQE3 5/20 0.38
TUBB6 Q9BUF5 5/20 0.38
TUBB2B Q9BVA1 5/20 0.38
TUBB1 Q9H4B7 5/20 0.38
BRD4 O60885 1/20 0.37
IMPDH2 P12268 1/20 0.37
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27021650 0.81 BRD4 (0.45) BRD4IMPDH2LTA4HADRA1AADRA1D
SCHEMBL20155994 0.80 CTSA (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL27895629 0.80 SMN1; SMN2 (0.52) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL24026461 0.79 TUBB4A (0.40) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL22041213 0.79 BRD4 (0.38) BRD4TSHRLTA4HADRA1ACTSA
SCHEMBL20155668 0.77 TUBB4A (0.40) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL24288066 0.77 TUBB4A (0.40) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL20150096 0.77 NOTUM (0.46) TSHRALDH1A1MAPT
SCHEMBL20150120 0.76 TSHR (0.39) ALOX15TSHRNPC1ALDH1A1TP53
SCHEMBL11444284 0.74 PLAU (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-10 US disclosed
US-11220508-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2022-01-11 US disclosed
US-11174265-B2 2021-11-16 US disclosed
US-20210230163-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-07-29 US disclosed
US-10793574-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-10-06 US disclosed
US-20190284194-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-09-19 US disclosed
US-10323036-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2019-06-18 US disclosed
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-07 US disclosed
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-07 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11220508-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TUBB4A 2425/4885TUBB 1669/4885TUBA3C 2447/4885
US-10793574-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TUBB4A 2425/4885TUBB 1669/4885TUBA3C 2447/4885
US-10323036-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TUBB4A 2425/4885TUBB 1669/4885TUBA3C 2447/4885
US-20210230163-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TUBB4A 2425/4885TUBB 1669/4885TUBA3C 2447/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TUBB4A 2425/4885TUBB 1669/4885TUBA3C 2447/4885
US-20190284194-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TUBB4A 2425/4885TUBB 1669/4885TUBA3C 2447/4885
US-11174265-B2 TYK2, JAK2, JAK1 TUBB4A 1544/4885TUBB 844/4885TUBA3C 1424/4885
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TUBB4A 2425/4885TUBB 1669/4885TUBA3C 2447/4885
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TUBB4A 2425/4885TUBB 1669/4885TUBA3C 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.